1. Impact of Incretin-Based Therapies on Adipokines and Adiponectin
   Habib Yaribeygi et al, 2021, Journal of Diabetes Research CrossRef
2. Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials
   Luis E. Simental‐Mendía et al, 2021, British Journal of Clinical Pharmacology CrossRef
3. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota
   Yuanfeng Lyu et al, 2019, Life Sciences CrossRef
4. Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial
   Xubin Yang et al, 2024, Heliyon CrossRef
5. Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials
   Jonathan J. H. Bray et al, 2021, Diabetes, Obesity and Metabolism CrossRef
6. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials
   Luis E. Simental-Mendía et al, 2021, Diabetes Research and Clinical Practice CrossRef
7. Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
   Jie Zhang et al, 2022, International Journal of Clinical Practice CrossRef